Skip to main content
Log in

6-Mercaptopurine: high-dose 24-h infusions in goats

  • Original Papers
  • Clinical Oncology or Epidemiology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Summary

In vitro investigations have indicated the need for both prolonged exposure to 6-mercaptopurine (6MP) and the use of high concentrations to achieve maximal cell kill. After the customary oral administration the bioavailability of 6MP appeared to be low, and i.v. bolus injections resulted in short-live high concentrations of 6MP, so prolonged infusions seemed rational. To test the feasibility of this approach 24-h infusions were given to goats. We used our improved HPLC method to quantitate 6MP and 6MP riboside (6MPR) in plasma, CSF, and urine. The concentrations of 6MPR were in excess of those of 6MP. Since 6MPR can easily be converted to 6MP, 6MPR acts as a depot for 6MP. Penetration of both 6MP and 6MPR into CSF was excellent. Of the total dose administered, 38% to 68% could be accounted for in the urine, with about equal amounts of 6MP and 6MPR. At doses of 20 and 10 mg kg-1 h-1 total concentrations of 6MP and 6MPR in excess of 100 μM were reached during 24-h infusions. However, all three experimental animals died due to toxicity. A dose of 2 mg kg-1 h-1 was tolerated; the total steady state concentration of 6MP and 6MPR in two experiments was about 10 μM. We conclude that the prolonged infusion of 6MP is feasible, and in view of the excellent penetration of 6MP and 6MPR into CSF, studies using prolonged infusions of thiopurines are warranted in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

6MP(R):

6-mercaptopurine (riboside)

6TG(R):

6-thioguanine (riboside)

CSF:

cerebrospinal fluid

DTT:

dithiothreitol

References

  • Abreu RA De, Baal JM van, Schouten TJ, Schretlen EDAM, Bruyn CHMM de (1982) High-performance liquid chromatographic determination of plasma 6-mercaptopurine in clinically relevant concentrations. J Chromatogr 227:526–533

    Google Scholar 

  • Baal JM van, Leeuwen MB van, Schouten TJ, Abreu RA De (1984) Sensitive high-performance liquid chromatographic determination of 6-mercaptopurine, 6-thioguanine, 6-mercaptopurine riboside and 6-thioguanosine in biological fluids. J Chromatogr 336:422–428

    Google Scholar 

  • Brox LW, Birkett L, Belch A (1981) Clinical pharmacology of oral thioguanine in acute myelogenous leukemia. Cancer Chemother Pharmacol 6:35–38

    Google Scholar 

  • Ding TL, Benet LZ (1979) Comparative bioavailability and pharmacokinetic studies of azathioprine and 6-mercaptopurine in the Rhesus monkey. Drug Metab Dispos 7:373–377

    Google Scholar 

  • Duttera MJ, Carolla RL, Gallelli JF, Gullion DS, Keim DE, Henderson ES (1972) Hematuria and crystalluria after high-dose 6-mercaptopurine administration. N Engl J Med 287:292–294

    Google Scholar 

  • King ME, Honeysett JM, Howell SB (1983) Regulation of de novo purine synthesis in human bone marrow mononuclear cells by hypoxanthine. J Clin Invest 72:965–970

    Google Scholar 

  • LePage GA (1977) Purine antagonists. In: Becker FF (ed) Cancer: comprehensive treatise, vol V. Plenum Press, New York, pp 309–326

    Google Scholar 

  • Lippens RJJ (1981) Methotrexate in the central nervous system prophylaxis of children with acute lymphoblastic leukemia. Thesis Catholic University of Nijmegen. Mefar, Beetsterzwaag, The Netherlands

    Google Scholar 

  • Mackillop WJ, Ciampi A, Till JE, Buick RN (1983) A stem cell model of human tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst 70:9–16

    Google Scholar 

  • Matsumura S, Hoshino T, Weizsaecker M, Deen DF (1983) Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. Cancer Treat Rep 67:475–480

    Google Scholar 

  • Mellett LB (1977) Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Cancer Treat Rep 61:527–531

    Google Scholar 

  • Narang PK, Chatterji DC, O'Neill D, Poplack DG (1983) Pharmacokinetics of 6-mercaptopurine (6MP) in the monkey. I. Disposition from plasma and cerebrospinal fluid following i.v. bolus. Drug Metab Dispos 11:5–9

    Google Scholar 

  • Nelson JA, Cserr HF, Chu SH (1974) Distribution of 6-mercaptopurine ribonucleoside and other purine analogs to brain. Cancer Res 34:1889–1891

    Google Scholar 

  • Paterson ARP, Tidd DM (1975) 6-Thiopurines. Handbook of pharmacology, XXXVIII/2, antineoplastic and immunosuppressive agents. Springer, Berlin Heidelberg New York, pp 384–403

    Google Scholar 

  • Regelson W, Holland JF, Gold GL, Lynch J, Olson KB, Horton J, Hall TC, Krant M, Colsky J, Miller SP, Owens A (1967) 6-Mercaptopurine (NSC-755) given intravenously at weekly intervals to patients with advanced cancer. Cancer Chemother Rep 51:277–282

    Google Scholar 

  • Rupniak HTh, Dennis LY, Hill BT (1983) An intercomparison of in vitro assays for assessing cytotoxicity after a 24 h exposure to anticancer drugs. Tumori 69:37–42

    Google Scholar 

  • Scholar EM, Calabresi P (1979) Increased activity of alkaline phosphatase in leukemic cells from patients resistant to thiopurines. Biochem Pharmacol 28:445–446

    Google Scholar 

  • Schouten TJ, Abreu RA De, Bruyn CHMM de, Kleijn E van der, Oosterbaan MJM, Schretlen EDAM, Vaan GAM de (1984) 6-Mercaptopurine: pharmacokinetics in animals and preliminary results in children. Adv Exp Med Biol 165B:367–370

    Google Scholar 

  • Schouten TJ, Abreu RA De, Bruyn CHMM de, Kleijn E van der, Oosterbaan MJM, Schretlen EDAM, Vaan GAM de (1985) 6-Mercaptopurine: oral administration and i.v. bolus injections in dogs. Eur Paediatr Haematol Oncol 2:93–98

    Google Scholar 

  • Schouten TJ, Abreu RA De, Schretlen EDAM, Vaan GAM de, Kleijn E van der (1986) 6-Mercaptopurine: total body autoradiograms and plasma concentration-time curves of 6MP and metabolites from Marmoset monkeys. Ped Hematol Oucol 3: 113–122

    Google Scholar 

  • Strobel-Stevens JD, Dareer SM El, Trader MW, Hill DL (1982) Some biochemical characteristics of L1210 cell lines resistant to 6-mercaptopurine and 6-thioguanine and with increased sensitivity to methotrexate. Biochem Pharmacol 31:3133–3137

    Google Scholar 

  • Tattersall MHN, Slowiaczek P, Fazio A De (1983) Regional variation in human extracellular purine levels. J Lab Clin Med 102:411–420

    Google Scholar 

  • Tidd DM, Paterson ARP (1974a) Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34:733–737

    Google Scholar 

  • Tidd DM, Paterson ARP (1974b) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34:738–746

    Google Scholar 

  • Tidd DM, Kim SC, Horakova K, Moriwaki A, Paterson ARP (1972) A delayed cytotoxic reaction for 6-mercaptopurine. Cancer Res 32:317–322

    Google Scholar 

  • Wagner JG (1975) Fundamentals of clinical pharmacokinetics, 1st edn. Drug Intelligence Publications, Hamilton, Ill, USA

    Google Scholar 

  • Wotring LL, Roti Roti JL (1980) Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res 40:1458–1462

    Google Scholar 

  • Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, Poplack DG (1983) Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308:1005–1009

    Google Scholar 

  • Zimm S, Grygiel JJ, Strong JM, Monks TJ, Poplack DG (1984) Identification of 6-mercaptopurine riboside in patients receiving 6-mercaptopurine as a prolonged intravenous infusion. Biochem Pharmacol 24:4089–4092

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

Supported by the “Queen Wilhelmina Fund” (Dutch Cancer Society), Grant NUKC Kg 81-2

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schouten, T.J., De Abreu, R.A., Schretlen, E.D.A.M. et al. 6-Mercaptopurine: high-dose 24-h infusions in goats. J Cancer Res Clin Oncol 112, 61–66 (1986). https://doi.org/10.1007/BF00394941

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00394941

Key words

Navigation